Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04776941 · ClinicalTrials.gov registry record · NA

Expressive Writing for the Management of Stress in Cancer Survivors

A NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
NA
Development phase
414
Enrollment target
1
Study location

NCT04776941 is a NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 414 participants, below the 1,138-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04776941, a NA study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
NA
Development phase
414 participants
Enrollment target
1
Study location

Study Summary

This clinical trial evaluates the effect of expressive writing for the management of stress in cancer survivors. Cancer diagnosis and treatment are associated with increased stress in cancer survivors related to concerns about family, career, relationships, finances, side effects of treatment, and death. This stress can be further exacerbated by social upheavals such as the COVID-19 pandemic. For safety reasons, many patients are isolated with restricted access to in-person health care and reduced social interaction with family and friends. Together with the economic uncertainties that come with this pandemic, these factors are likely to increase cancer survivors' stress levels. Expressive writing may provide a medium through which cancer survivors confront stressors and find meaning in their experience. The goal of this trial is to learn more about the experiences of cancer survivors during stressful times.

Conditions Studied

Malignant Solid Neoplasm Hematopoietic and Lymphoid Cell Neoplasm

Interventions

  • OTHER Quality-of-Life Assessment
  • BEHAVIORAL Behavioral Intervention

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 414 participants
Start Date 2020-08-07
Est. Completion 2028-12-31
Phase NA

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04776941

The ClinicalTrials.gov registry entry for NCT04776941 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 414 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,138-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (64% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Quality-of-Life Assessment is the first listed.

NCT04776941 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04776941 about?

NCT04776941 is a clinical study titled "Expressive Writing for the Management of Stress in Cancer Survivors". This clinical trial evaluates the effect of expressive writing for the management of stress in cancer survivors. Cancer diagnosis and treatment are associated with increased stress in cancer survivors related to concerns about family, career, relationships, finances, side effects of treatment, and d...

What is the current status of trial NCT04776941?

This trial is currently recruiting. It is a NA study. The enrollment target is 414 participants. The study started on 2020-08-07. Estimated completion is 2028-12-31.

What conditions does trial NCT04776941 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm.

What interventions are being tested in trial NCT04776941?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Behavioral Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT04776941?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04776941 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Malignant Solid Neoplasm

All registered trials for this condition

Hematopoietic and Lymphoid Cell Neoplasm

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.